<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512451942</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512451942</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Short Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epstein–Barr virus, latitude and multiple sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Disanto</surname><given-names>Giulio</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451942">1</xref>
<xref ref-type="aff" rid="aff2-1352458512451942">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pakpoor</surname><given-names>Julia</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451942">1</xref>
<xref ref-type="aff" rid="aff2-1352458512451942">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Morahan</surname><given-names>Julia M</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451942">1</xref>
<xref ref-type="aff" rid="aff2-1352458512451942">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hall</surname><given-names>Carolina</given-names></name>
<xref ref-type="aff" rid="aff4-1352458512451942">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Meier</surname><given-names>Ute C</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512451942">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Giovannoni</surname><given-names>Gavin</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512451942">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ramagopalan</surname><given-names>Sreeram V</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451942">1</xref>
<xref ref-type="aff" rid="aff2-1352458512451942">2</xref>
<xref ref-type="aff" rid="aff3-1352458512451942">3</xref>
<xref ref-type="aff" rid="aff4-1352458512451942">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512451942"><label>1</label>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK</aff>
<aff id="aff2-1352458512451942"><label>2</label>Nuffield Department of Clinical Neurosciences (Clinical Neurology), University of Oxford, Oxford, UK</aff>
<aff id="aff3-1352458512451942"><label>3</label>Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, UK</aff>
<aff id="aff4-1352458512451942"><label>4</label>London School of Hygiene and Tropical Medicine, London, UK</aff>
<author-notes>
<corresp id="corresp1-1352458512451942">Dr Sreeram V Ramagopalan, Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, UK. Email: <email>s.ramagopalan@qmul.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>362</fpage>
<lpage>365</lpage>
<history>
<date date-type="received">
<day>7</day>
<month>3</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Several lines of evidence support a role for Epstein–Barr virus (EBV) in the aetiology of multiple sclerosis (MS). This includes the observation that nearly all MS patients show serological markers of past EBV infection. Given the well-known association between MS prevalence and latitude, we investigated whether EBV seropositivity also increases with distance from the equator. We found that the proportion of EBV positive individuals is positively associated with latitude independently of MS status (odds ratio = 1.06, 95% CI = 1.02–1.09, <italic>p</italic> = 0.002). Latitude-related factors may be implicated in the immune response to EBV and its role in MS aetiology.</p>
</abstract>
<kwd-group>
<kwd>Epstein–Barr virus</kwd>
<kwd>interaction</kwd>
<kwd>latitude</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>vitamin D</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458512451942" sec-type="intro">
<title>Introduction</title>
<p>It is widely acknowledged that environmental factors influence the risk of developing multiple sclerosis (MS). In addition to vitamin D deficiency and smoking history, epidemiological evidence strongly implicates the Epstein–Barr virus (EBV) in MS aetiology.<sup><xref ref-type="bibr" rid="bibr1-1352458512451942">1</xref></sup> The risk of MS is extremely low among EBV negative individuals and augmented in those with either high anti-EBV antibody titres or a history of symptomatic EBV infection (infectious mononucleosis).<sup><xref ref-type="bibr" rid="bibr2-1352458512451942">2</xref><xref ref-type="bibr" rid="bibr3-1352458512451942"/>–<xref ref-type="bibr" rid="bibr4-1352458512451942">4</xref></sup> Although the vast majority of MS patients are seropositive for EBV antibodies, the frequency of seropositivity varies from study to study ranging from 80% to 100%. Since the prevalence of MS increases with latitude, we reviewed all studies assessing EBV seroprevalence in MS patients and controls and investigated whether this also varies according to latitude. Our <italic>a priori</italic> hypothesis was that EBV seroprevalence would increase with distance from the equator.</p>
</sec>
<sec id="section2-1352458512451942" sec-type="methods">
<title>Methods</title>
<p>PubMed searches were undertaken to identify studies investigating the association between MS and EBV using the terms (“herpesvirus 4, human” [MeSH Terms] OR “human herpesvirus 4” [All Fields] OR (“epstein” [All Fields] AND “barr” [All Fields] AND “virus” [All Fields]) OR “epstein barr virus” [All Fields]) AND (“multiple sclerosis” [MeSH Terms] OR (“multiple” [All Fields] AND “sclerosis” [All Fields]) OR “multiple sclerosis” [All Fields]). EMBASE was searched for abstracts using the terms “multiple sclerosis” [All fields] AND “epstein barr virus” [All fields]. Twenty two studies assessing EBV infection in adult MS patients and unrelated controls were found. After excluding those studies in which latitude could not be precisely determined (<italic>n</italic> = 2) and studies performed in the southern hemisphere (<italic>n</italic> = 1), 19 studies were used for analysis (Supplementary material). The relation between latitude and EBV seroprevalence was investigated using logistic regression and assessing differences between proportions. Missing data were excluded from the analysis. Statistical analyses were performed using R.</p>
</sec>
<sec id="section3-1352458512451942" sec-type="results">
<title>Results</title>
<p>All studies were performed between 29° and 65° N latitude. We found no evidence of either study heterogeneity (<italic>I</italic><sup>2</sup> = 1.5% (95% confidence interval [CI] = 0–44.5%)) or publication bias (Egger <italic>p</italic> = 0.06). We first investigated whether MS status and latitude were significant predictors of EBV status using logistic regression. As expected the strongest predictor of EBV seroprevalence was MS status (odds ratio [OR] = 4.41, 95% CI = 2.4–8.08, <italic>p</italic> &lt; 0.001). However, latitude was also positively associated with EBV status independently of MS status (OR = 1.06, 95% CI = 1.02–1.09, <italic>p</italic> = 0.002). When mean age and sex ratio were also included in the regression model, the effect of latitude was attenuated but still present (OR = 1.05, 95% CI = 1.0003–1.119, <italic>p</italic> = 0.038). Notably among MS patients, 7 of the 9 studies performed at the highest latitudes (46°–65° N) reported an EBV seroprevalence of 100% as compared with 2 of the remaining 10 studies performed at the lowest latitudes (29°–45° N) (<xref ref-type="fig" rid="fig1-1352458512451942">Figure 1</xref>).</p>
<fig id="fig1-1352458512451942" position="float">
<label>Figure 1.</label>
<caption>
<p>(a) Distribution of Epstein–Barr virus (EBV) seroprevalence in multiple sclerosis (MS) patients according to latitude; (b) distribution of EBV seroprevalence in controls according to latitude; (c) EBV seroprevalence with 95% confidence interval in ≥42° versus &lt;42° N latitude groups among MS patients (blue) and controls (red); (d) subgroup analysis of studies using ELISA.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451942-fig1.tif"/></fig>
<p>Given the association between vitamin D deficiency and MS risk,<sup><xref ref-type="bibr" rid="bibr1-1352458512451942">1</xref></sup> we grouped studies into those conducted below and above 42° N latitude, since this latitude has been considered as a theoretical cut-off point above which most ultraviolet B (UVB) radiation is absorbed by the atmosphere and vitamin D production is more difficult.<sup><xref ref-type="bibr" rid="bibr5-1352458512451942">5</xref>,<xref ref-type="bibr" rid="bibr6-1352458512451942">6</xref></sup> EBV seroprevalence was substantially higher in the ≥42° N group in both MS patients and controls (MS <italic>p</italic> = 0.001, controls <italic>p</italic> = 7.17 × 10<sup>−11</sup>) (<xref ref-type="fig" rid="fig1-1352458512451942">Figure 1c</xref>). Different methods for antibody detection have different sensitivity and specificity for EBV.<sup><xref ref-type="bibr" rid="bibr7-1352458512451942">7</xref></sup> The most frequently used method was enzyme-linked immunosorbent assay (ELISA) tests. Performing a subgroup analysis of those studies using ELISA (<italic>n</italic> = 9) did not change the results (MS <italic>p</italic> = 4.91 × 10<sup>−09</sup>, controls <italic>p</italic> = 4.57 × 10<sup>−06</sup>) (<xref ref-type="fig" rid="fig1-1352458512451942">Figure 1d</xref>). The proportion of EBV positive cases and controls with 95% CI according to latitude groups and their differences are presented in <xref ref-type="table" rid="table1-1352458512451942">Table 1</xref>.</p>
<table-wrap id="table1-1352458512451942" position="float">
<label>Table 1.</label>
<caption>
<p>Difference between proportions of Epstein–Barr virus (EBV) positive multiple sclerosis (MS) patients and controls by latitude group (&lt;42° versus ≥42° N).</p>
</caption>
<graphic alternate-form-of="table1-1352458512451942" xlink:href="10.1177_1352458512451942-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4">MS</th>
<th align="center" colspan="4">Controls</th>
</tr>
<tr>
<th/>
<th align="left">&lt;42° N (<italic>n</italic>=884)</th>
<th align="left">≥42° N (<italic>n</italic>=1291)</th>
<th align="left">Difference</th>
<th align="left"><italic>p-</italic>value</th>
<th align="left">&lt;42° N (<italic>n</italic>=899)</th>
<th align="left">≥42° N (<italic>n</italic>=1584)</th>
<th align="left">Difference</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Proportion EBV +</bold></td>
<td>0.966</td>
<td>0.988</td>
<td>0.022</td>
<td>0.001</td>
<td>0.880</td>
<td>0.952</td>
<td>0.072</td>
<td>7.17×10<sup>−11</sup></td>
</tr>
<tr>
<td><bold>95% CI lower limit</bold></td>
<td>0.951</td>
<td>0.979</td>
<td>0.007</td>
<td/>
<td>0.856</td>
<td>0.940</td>
<td>0.048</td>
<td/>
</tr>
<tr>
<td><bold>95% CI upper limit</bold></td>
<td>0.977</td>
<td>0.993</td>
<td>0.036</td>
<td/>
<td>0.900</td>
<td>0.962</td>
<td>0.097</td>
<td/>
</tr>
<tr>
<th/>
<th align="center" colspan="4">MS (ELISA)</th>
<th align="center" colspan="4">Controls (ELISA)</th>
</tr>
<tr>
<th/>
<th align="left">&lt;42° N (<italic>n</italic>=217)</th>
<th align="left">≥42° N (<italic>n</italic>=763)</th>
<th align="left">Difference</th>
<th align="left"><italic>p</italic>-value</th>
<th align="left">&lt;42° N (<italic>n</italic>=215)</th>
<th align="left">≥42° N (<italic>n</italic>=595)</th>
<th align="left">Difference</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
<tr>
<td><bold>Proportion EBV +</bold></td>
<td>0.889</td>
<td>0.980</td>
<td>0.091</td>
<td>4.91×10<sup>−9</sup></td>
<td>0.814</td>
<td>0.928</td>
<td>0.114</td>
<td>4.57×10<sup>−6</sup></td>
</tr>
<tr>
<td><bold>95% CI lower limit</bold></td>
<td>0.838</td>
<td>0.967</td>
<td>0.045</td>
<td/>
<td>0.754</td>
<td>0.903</td>
<td>0.055</td>
<td/>
</tr>
<tr>
<td><bold>95% CI upper limit</bold></td>
<td>0.926</td>
<td>0.989</td>
<td>0.137</td>
<td/>
<td>0.862</td>
<td>0.947</td>
<td>0.173</td>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section4-1352458512451942" sec-type="discussion">
<title>Discussion</title>
<p>We carried out a systematic review of EBV studies in MS and showed that EBV seroprevalence in both MS patients and controls is positively associated with latitude. This effect was still present when the analysis was corrected for MS status, mean age and sex ratio with an OR of 1.05 per degree increase. Notably, the latitude effect was seen in both MS cases and controls suggesting that the relation between latitude and EBV is not specific to MS but likely represents a general phenomenon acting at the population level.</p>
<p>The main limitation of this study is the variation in methodologies used and antibodies tested to detect past EBV infection. This variation represents a significant potential confounding factor and could contribute to explain these observations. However the increase by latitude is still present when a more homogeneous group of studies (those using ELISA based tests) was considered, although ELISA tests are approximately 90% sensitive and specific.<sup><xref ref-type="bibr" rid="bibr7-1352458512451942">7</xref></sup></p>
<p>Despite these limitations, it is plausible that latitude-related factors could be truly influencing EBV infection. Genetic, social and climatic differences are all likely to play a role. If socioeconomic factors were primarily involved, one would expect to see an inverse relation between latitude and EBV status since worldwide hygiene generally increases with latitude (unless it is a socioeconomic effect on ability to detect EBV which would then fit the data). Among other candidate factors is vitamin D deficiency and interestingly the latitude effect appeared particularly strong when studies were grouped into those conducted above and below a latitude threshold which has a functional effect on vitamin D production. Notably, a common thread seems to link EBV and vitamin D in disease aetiology. The latter is a potent immune modulator against bacterial and viral infections and vitamin D levels inversely correlate with EBV DNA load.<sup><xref ref-type="bibr" rid="bibr8-1352458512451942">8</xref>,<xref ref-type="bibr" rid="bibr9-1352458512451942">9</xref></sup> Vitamin D deficiency could impair the immune response to EBV and increase either susceptibility to EBV infection or its control after infection has occurred, leading to viral reactivation, augmented antibody production and therefore increased laboratory detection.</p>
<p>These considerations provide insights into how EBV may be involved in MS aetiology. If EBV was a causative factor in MS, vitamin D deficiency could enhance its pathogenic role. The association between EBV and MS could also be merely a consequence of vitamin D deficiency predisposing to both MS and EBV infection but this appears unlikely given the amount of evidence for EBV in MS and studies showing that the link between EBV and risk of MS is not confounded by vitamin D status.<sup><xref ref-type="bibr" rid="bibr9-1352458512451942">9</xref>,<xref ref-type="bibr" rid="bibr10-1352458512451942">10</xref></sup> Future prospective studies should investigate whether risk of EBV infection and/or EBV antibody titres are influenced by vitamin D status.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by a research fellowship FISM Fondazione Italiana Sclerosi Multipla-Cod.: 2010/B/5 and the Medical Research Council (grant number G0801976). The study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. All authors state that this research was carried out independently of the influence of funding bodies.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>Dr Disanto is funded by a research fellowship FISM-Fondazione Italiana Sclerosi Multipla-Cod. 2010/B/5. Julia Pakpoor reports no disclosures. Dr Morahan is funded by the MS Society of Australia and the UK. Carolina Hall reports no disclosures. Dr Meier reports no disclosures. Dr Giovannoni serves on scientific advisory boards for Merck Serono and Biogen Idec and Vertex Pharmaceuticals; served on the editorial board of Multiple Sclerosis; has received speaker honoraria from Bayer Schering Pharma, Merck Serono, Biogen Idec, Pfizer Inc, Teva Pharmaceutical Industries Ltd.–sanofiaventis, Vertex Pharmaceuticals, Genzyme Corporation, Ironwood, and Novartis; has served as a consultant for Bayer Schering Pharma, Biogen Idec, GlaxoSmithKline, Merck Serono, Protein Discovery Laboratories, Teva Pharmaceutical Industries Ltd.–sanofi-aventis, UCB, Vertex Pharmaceuticals, GW Pharma, Novartis, and FivePrime; serves on the speakers bureau for Merck Serono; and has received research support from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, UCB, Merz Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd.–sanofi-aventis, GW Pharma, and Ironwood. Dr Ramagopalan receives research support from the Multiple Sclerosis Society of the United Kingdom</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512451942">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramagopalan</surname><given-names>SV</given-names></name>
<name><surname>Dobson</surname><given-names>R</given-names></name>
<name><surname>Meier</surname><given-names>UC</given-names></name>
<name><surname>Giovannoni</surname><given-names>G.</given-names></name>
</person-group> <article-title>Multiple sclerosis: risk factors, prodromes, and potential causal pathways</article-title>. <source>Lancet Neurol</source> <year>2010</year>; <volume>9</volume>: <fpage>727</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512451942">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levin</surname><given-names>LI</given-names></name>
<name><surname>Munger</surname><given-names>KL</given-names></name>
<name><surname>O’Reilly</surname><given-names>EJ</given-names></name>
<name><surname>Falk</surname><given-names>KI</given-names></name>
<name><surname>Ascherio</surname><given-names>A.</given-names></name>
</person-group> <article-title>Primary infection with the Epstein–Barr virus and risk of multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>67</volume>: <fpage>824</fpage>–<lpage>830</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512451942">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ascherio</surname><given-names>A</given-names></name>
<name><surname>Munger</surname><given-names>KL.</given-names></name>
</person-group> <article-title>Environmental risk factors for multiple sclerosis. Part I: the role of infection</article-title>. <source>Ann Neurol</source> <year>2007</year>; <volume>61</volume>: <fpage>288</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512451942">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Handel</surname><given-names>AE</given-names></name>
<name><surname>Williamson</surname><given-names>AJ</given-names></name>
<name><surname>Disanto</surname><given-names>G</given-names></name>
<name><surname>Handunnetthi</surname><given-names>L</given-names></name>
<name><surname>Giovannoni</surname><given-names>G</given-names></name>
<name><surname>Ramagopalan</surname><given-names>SV.</given-names></name>
</person-group> <article-title>An updated meta- analysis of risk of multiple sclerosis following infectious mononucleosis</article-title>. <source>PLoS One</source> <year>2010</year>; <fpage>5</fpage>.</citation>
</ref>
<ref id="bibr5-1352458512451942">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ascherio</surname><given-names>A</given-names></name>
<name><surname>Munger</surname><given-names>KL.</given-names></name>
</person-group> <article-title>Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors</article-title>. <source>Ann Neurol</source> <year>2007</year>; <volume>61</volume>: <fpage>504</fpage>–<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512451942">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Webb</surname><given-names>AR</given-names></name>
<name><surname>Kline</surname><given-names>L</given-names></name>
<name><surname>Holick</surname><given-names>MF.</given-names></name>
</person-group> <article-title>Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin</article-title>. <source>J Clin Endocrinol Metab</source> <year>1988</year>; <volume>67</volume>: <fpage>373</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512451942">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Ory</surname><given-names>F</given-names></name>
<name><surname>Guisasola</surname><given-names>ME</given-names></name>
<name><surname>Sanz</surname><given-names>JC</given-names></name>
<name><surname>Garcia-Bermejo</surname><given-names>I.</given-names></name>
</person-group> <article-title>Evaluation of four commercial systems for the diagnosis of Epstein–Barr virus primary infections</article-title>. <source>Clin Vaccine Immunol</source> <year>2011</year>; <volume>18</volume>: <fpage>444</fpage>–<lpage>448</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512451942">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beard</surname><given-names>JA</given-names></name>
<name><surname>Bearden</surname><given-names>A</given-names></name>
<name><surname>Striker</surname><given-names>R.</given-names></name>
</person-group> <article-title>Vitamin D and the anti-viral state</article-title>. <source>J Clin Virol</source> <year>2011</year>; <volume>50</volume>: <fpage>194</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512451942">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lucas</surname><given-names>RM</given-names></name>
<name><surname>Ponsonby</surname><given-names>AL</given-names></name>
<name><surname>Dear</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Current and past Epstein–Barr virus infection in risk of initial CNS demyelination</article-title>. <source>Neurology</source> <year>2011</year>; <volume>77</volume>: <fpage>371</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512451942">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Munger</surname><given-names>KL</given-names></name>
<name><surname>Levin</surname><given-names>LI</given-names></name>
<name><surname>O’Reilly</surname><given-names>EJ</given-names></name>
<name><surname>Falk</surname><given-names>KI</given-names></name>
<name><surname>Ascherio</surname><given-names>A.</given-names></name>
</person-group> <article-title>Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>1185</fpage>–<lpage>1193</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>